Search Results

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

The third quarter offered positive signals for job seekers and talent acquisition teams. Explore BioSpace’s Biopharma Job Market Report Q3 2026 to get a closer look at hiring trends, workforce reductions and the evolving employment landscape across the industry.

From engineering to science/R&D, these top seven biopharma disciplines each have hundreds, and in one case over 1,000, positions posted on BioSpace.

The $100,000 H-1B visa fee has significantly affected who biopharma companies hire, according to two experts. It’s not the only program adjustment affecting foreign-born job seekers’ odds of working in the U.S.

This guide explores the evolving role of podcasts, webinars, and thought leadership programs in biopharma and provides practical recommendations for public relations agencies, corporate communications teams, and commercial marketers looking to elevate their visibility and influence.

As biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D and clinical disciplines, according to BioSpace data. Several other locations and functions have also been going strong.

Gain the latest insights into the biopharma hiring landscape with BioSpace’s Biopharma Job Market Report Q2 2026. Explore the trends shaping talent acquisition, from rising job postings and sustained R&D hiring to the market activity signaling stronger hiring demand ahead.

After barely growing in 2024, biopharma employment in Massachusetts dropped 3.1% last year. R&D jobs dipped even more, by 3.9%. Biomanufacturing, however, went up.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.